Cargando…
Sorafenib plus partial splenic embolism for treatment of hepatocellular carcinoma Barcelona stage C combined with hypersplenism: a case series
BACKGROUND: Sorafenib is mainly used to treat patients with hepatocellular carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) stage C, many of whom also have severe cirrhosis. However, hypersplenism and digestive tract hemorrhage are common complications of cirrhosis, which increase the risk and d...
Autores principales: | Zeng, Jianting, Wang, Chunmei, Wang, Yu, Luo, Zhenhua, Zhang, Yanlin, Luo, Xianzhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216376/ https://www.ncbi.nlm.nih.gov/pubmed/34139869 http://dx.doi.org/10.1177/03000605211023351 |
Ejemplares similares
-
Effect of partial splenic embolization on transarterial chemoembolization for hepatocellular carcinoma with hypersplenism
por: Liu, Jibing, et al.
Publicado: (2021) -
Repeated partial splenic artery embolization for hypersplenism improves platelet count
por: Tan, Youwen, et al.
Publicado: (2022) -
Splenic artery embolization with detachable balloons for
hypersplenism
por: Pang, Xiaoxi, et al.
Publicado: (2018) -
Comparison of three embolic materials at partial splenic artery embolization for hypersplenism: clinical, laboratory, and radiological outcomes
por: Zaitoun, Mohamed M. A., et al.
Publicado: (2021) -
Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria
por: Araten, David J, et al.
Publicado: (2014)